To the Editor: Rare adverse effects of new drugs are often missed in prospective trials.* Disopyramide (Norpace) has been on the United States market since 1977 and began to be used at this medical center in 1978. Shortly thereafter, we suspected that disopyramide might occasionally induce dysrhythmias. We therefore retrospectively reviewed the first 50 disopyramide-treated inpatients at our hospital. In all but one patient (Case 3), disopyramide had been given to suppress premature ventricular contractions. Case 1 was a 67-year-old man with coronary-artery disease and marked left ventricular dilatation, who was admitted with quinidine-induced thrombocytopenia. Disopyramide, 300 mg by mouth. . .
All Science Journal Classification (ASJC) codes